IndiaCatalog.com
India News
Search Web Directory
News Home
Cipla arm InvaGen Pharma gets USFDA nod for neuropathic pain management drug
Posted on 22nd July 2019
Drug major Cipla Monday said its subsidiary InvaGen Pharmaceuticals has received final approval from the US health regulator for Pregabalin Capsules, indicated for management of neuropathic pain associated with certain illnesses.

InvaGen has received approval from the the United States Food and Drug Administration (USFDA) for the drug in the strengths of 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg and 300mg, Cipla said in a regulatory filing.

Cipla said the approved product is a generic therapeutic equivalent version of Pfizer’s Lyrica.

Pregabalin capsules are indicated for management of neuropathic pain associated with diabetic peripheral neuropathy, management of postherpetic neuralgia, adjunctive therapy for the treatment of partial onset seizures in patients 17 years of age and older, management of fibromyalgia and management of neuropathic pain associated with spinal cord injury.

Quoting IQVIA data, Cipla said Lyrica had an estimated market size of USD 5.4 billion for 12 months ending March 2019. The product is available for shipping immediately, the company added. Shares of Cipla were trading 0.18 per cent lower at Rs 535.90 apiece on the BSE.

Related Companies: Cipla Limited - Mumbai.   

Other Latest News
'Very bad gift' from China, says Trump as death toll crosses 100,000-mark
Posted on 29th May 2020
The US President Donald Trump said on Thursday that coronavirus was a “very bad gift” from China to the rest of the world, as America surpassed the grim milestone of over 100,000 Covid-19-linked deaths.

All over the World the coronavirus, a very bad ‘gift’ from China, marches on. Not good! Trump said in a tweet.

Covid-19 impact: Auto biggies face low-liquidity risk, says study
Posted on 29th May 2020
The disruptions caused by the Covid-19 pandemic and subsequent lockdowns are leading to cash crunch in many companies.

Domestic brokerage firm Equirus has analysed companies based on the debt-to-equity ratio and debt-to-Ebitda ratio to assess companies that are at high-risk or ones that are relatively comfortable.

We remain firm in our resolve to ensure India's sovereignty: MEA on stand-off with China
Posted on 29th May 2020
Amid stand-off with Chinese troops in eastern Ladakh, India on Thursday said the country remains firm in its resolve to ensure sovereignty and national security.

According to reports, Chinese troops have crossed into Indian territory along the 3,500-km-long LAC in Ladakh and North Sikkim. While the LAC is the de-facto border between India and China, there is a lack of clearly demarcated boundary or fencing along the line.

'30 groups in India working on COVID-19 vaccine, development may cost $2-3 billion if done in a year'
Posted on 29th May 2020
There are about 30 groups in India, including big industry, startups and academics, who are working on COVID-19 vaccine development and about 20 of them are keeping a good pace, Government's top scientific advisor said on Thursday.

Addressing a media briefing on the coronavirus situation in the country, Professor K Vijay Raghavan, Principal Scientific Adviser to the Government of India, said the logistics of making COVID-19 vaccine accessible to everyone is a big challenge which is being discussed by the government now.

RBI imposes monetary penalty on Bank of India, Karnataka Bank for non-compliance on income recognition, NPA norms
Posted on 29th May 2020
The Reserve Bank of India (RBI) has imposed monetary penalty on three banks including Rs 5 crore on Bank of India for non-compliance with certain provisions of the directions issued by the apex bank.

The RBI has also imposed a monetary penalty of Rs 1.20 crore on Karnataka Bank and Rs 30 lakh on Saraswat Co-operative Bank, the central bank said.

» Post a FREE Classified Advertisement
Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.
Jobs in India India Real Estate Automobiles Matrimonials Beauty & Fitness

Add a comment for Cipla arm InvaGen Pharma gets USFDA nod for neuropathic pain management drug
Please only use this form to enter comments on the above company. All comments are reviewed before they are displayed on the web site. Not all comments may be displayed. Check back with us to see if your comments have been displayed.
If you want us to email the comments posted by users, please Subscribe by email
Name*
Comments*
Security Code*
 

Be the first person to write a business review for Cipla arm InvaGen Pharma gets USFDA nod for neuropathic pain management drug

Most Read News

RBI extends loan moratorium by three more months to August 31

TikTok owner's valuation exceeds $100 billion in private markets: Report

Covid-19 crisis: Indiabulls sacks over 2,000 employees to control expenses

Avenue Supermarts now 11th most valued Indian firm by market capitalisation

Mercury in Delhi crosses 45 degrees Celsius-mark, records highest temperature of season

More India News

Photo Gallery

Vijay(11 Images)Vijay
  India Web Directory
Business Profiles
Automotive Directory
IT/ITES/BPO Directory
Hotel Directory
Health Directory
Business Directory
Gems & Jewellery
Education Directory
Real Estate Directory
Agriculture Directory
Logistics Directory
Yellow Pages
NRI Guide
Photo Galleries
Global Web Directory
*** FREE India Classifieds
Order Premium Listings
Submit a Site
Business Reviews
Home
About us
Link to us
Advertise
Contact us
Google Search Keywords: India Catalog, IndiaCatalog, India Web Directory
    © 1999 - 2020 IndiaCatalog.com
    All Rights Reserved
Privacy Statement